The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking ...

On Saturday, Eli Lilly And Co (NYSE:LLY) released detailed results from the SUMMIT Phase 3 trial showing tirzepatide reduced ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the ...

In today’s health headlines, signs that sexually transmitted infections are declining. Could standing desks not be a great ...

Trump Suggests Use of Emergency Powers and the Military for Deportations Donald Trump addressed his plans for mass deportations in a social media post. He is expected to interview candidates for ...

A view of the new Beijing Stock Exchange at the Financial Street, in Beijing, China, November 15, 2021. REUTERS/Tingshu Wang/File Photo Asian stocks rose on Tuesday while U.S. bond yields and the ...

Stewart-Haas' sad demise belies its legacy of unlikely success (October 31, 2024, 7:00 PM ET) ...

Canadians will get child benefit cheques this week amid Canada Post strike Canadians will get child benefit cheques this week amid Canada Post strike Parents who are expecting child benefit ...